Loop diuretics association with Alzheimer's disease risk

Area of Science:

• Neurology
• Pharmacology
• Epidemiology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder with significant public health implications.
• Loop diuretics, such as bumetanide and furosemide, are commonly prescribed for conditions like heart failure.
• The potential impact of diuretic exposure on AD risk remains an area of investigation.

Purpose of the Study:

• To examine the association between exposure to bumetanide and furosemide and the subsequent risk of developing Alzheimer's disease.
• To investigate this association while controlling for socioeconomic status and congestive heart failure.

Main Methods:

• Utilized de-identified electronic health records from Stanford University via the Observational Medical Outcomes Partnership platform.
• Matched 5,839 Alzheimer's disease cases with 116,103 controls (1:20 ratio) older than 65 years, based on gender, race, ethnicity, and hypertension.
• Adjusted for socioeconomic status and other potential confounding variables.

Main Results:

• Bumetanide exposure was significantly associated with reduced Alzheimer's disease risk (OR = 0.23; 95% CI, 0.15-0.36; p = 4.0 × 10^-11).
• Furosemide exposure also showed a significant association with reduced Alzheimer's disease risk (OR = 0.42; 95% CI, 0.38-0.47; p < 2.0 × 10^-16).
• These associations remained significant after adjusting for socioeconomic status and other confounders.

Conclusions:

• History of bumetanide exposure is associated with a reduced risk of Alzheimer's disease.
• Furosemide, a common loop diuretic, is also associated with a reduced risk of Alzheimer's disease.
• Further replication and mechanistic studies are warranted to validate these findings.